Sentinel lymph node biopsy for melanoma: A critical update for dermatologists after two decades of experience

Clinics in Dermatology

Volumn 31, Issue 3, 2013, Pages 298-310

  Ross, Merrick I ^a   Gershenwald, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CUTANEOUS MELANOMA; DERMATOLOGIST; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; HISTOPATHOLOGY; HUMAN; IN-TRANSIT METASTASIS; LYMPH NODE DISSECTION; LYMPHEDEMA; MELANOMA; MORBIDITY; OVERALL SURVIVAL; PATIENT REFERRAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PUNCH BIOPSY; SENTINEL LYMPH NODE BIOPSY; SEROMA; SKIN ANAPHYLAXIS; WOUND COMPLICATION;

HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TIME FACTORS;

EID: 84876735736     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.004     Document Type: Article

References (75)

1. Balch C.M., Gershenwald J.E., Soong S.J., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
2. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992, 127:392-399.
3. Ross M.I., Gershenwald J.E. Evidence-based treatment of early-stage melanoma. J Surg Oncol 2011, 104:341-353.
4. Ross M.I. Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin. Semin Surg Oncol 1996, 12:394-401.
5. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19:3622-3634.
6. Morton D.L. Sentinel-node biopsy in melanoma. N Engl J Med 2007, 356:418-421.
7. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006, 355:1307-1317.
8. Balch C.M., Gershenwald J.E., Soong S.J., et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010, 28:2452-2459.
9. Calabro A., Singletary S.E., Balch C.M. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989, 124:1051-1055.
10. O'Brien C.J., Coates A.S., Petersen-Schaefer K., et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 1991, 162:310-314.
11. Slingluff C.L., Stidham K.R., Ricci W.M., et al. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 1994, 219:120-130.
12. Gershenwald J.E., Berman R.S., Porter G., et al. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 2000, 7:226-231.
13. Lee R.J., Gibbs J.F., Proulx G.M., et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000, 46:467-474.
14. Ballo M.T., Strom E.A., Zagars G.K., et al. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002, 52:964-972.
15. Sim F.H., Taylor W.F., Pritchard D.J., Soule E.H. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986, 61:697-705.
16. Cascinelli N., Morabito A., Santinami M., et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998, 351:793-796.
17. Balch C.M., Soong S., Ross M.I., et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000, 7:87-97.
18. Veronesi U., Adamus J., Bandiera D.C., et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977, 297:627-630.
19. Gershenwald J.E., Ross M.I. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med 2011, 364:1738-1745.
20. Ross M.I., Reintgen D., Balch C.M. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993, 9:219-223.
21. Reintgen D., Cruse C.W., Wells K., et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994, 220:759-767.
22. Thompson J.F., McCarthy W.H., Bosch C.M., et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995, 5:255-260.
23. Gershenwald J.E., Tseng C.H., Thompson W., et al. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998, 124:203-210.
24. Berger D.H., Feig B.W., Podoloff D., et al. Lymphoscintigraphy as a predictor of lymphatic drainage from cutaneous melanoma. Ann Surg Oncol 1997, 4:247-251.
25. Chakera A.H., Hesse B., Burak Z., et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging 2009, 36:1713-1742.
26. Uren R.F., Howman-Giles R., Thompson J.F., et al. Lymphoscintigraphy to identify sentinel lymph nodes in patients with melanoma. Melanoma Res 1994, 4:395-399.
27. Albertini J.J., Cruse C.W., Rapaport D., et al. Intraoperative radio-lympho-scintigraphy improves sentinel lymph node identification for patients with melanoma. Ann Surg 1996, 223:217-224.
28. Clary B.M., Brady M.S., Lewis J.J., Coit D.G. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001, 233:250-258.
29. Kapteijn B.A., Nieweg O.E., Liem I., et al. Localizing the sentinel node in cutaneous melanoma: gamma probe detection versus blue dye. Ann Surg Oncol 1997, 4:156-160.
30. Krag D.N., Meijer S.J., Weaver D.L., et al. Minimal-access surgery for staging of malignant melanoma. Arch Surg 1995, 130:654-658. discussion 659-60.
31. Sumner W.E., Ross M.I., Mansfield P.F., et al. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer 2002, 95:354-360.
32. Thompson J.F., Uren R.F., Shaw H.M., et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg 1999, 189:195-204.
33. Uren R.F., Howman-Giles R., Thompson J.F., et al. Interval nodes: the forgotten sentinel nodes in patients with melanoma. Arch Surg 2000, 135:1168-1172.
34. Uren R.F., Thompson J.F., Howman-Giles R. Sentinel nodes. Interval nodes, lymphatic lakes, and accurate sentinel node identification. Clin Nucl Med 2000, 25:234-236.
35. Uren R.F., Thompson J.F., Howman-Giles R., Shaw H.M. Melanoma metastases in triangular intermuscular space lymph nodes. Ann Surg Oncol 1999, 6:811.
36. Gershenwald J.E., Colome M.I., Lee J.E., et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998, 16:2253-2260.
37. Cook M.G., Green M.A., Anderson B., et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003, 200:314-319.
38. Prieto V.G., Clark S.H. Processing of sentinel lymph nodes for detection of metastatic melanoma. Ann Diagn Pathol 2002, 6:257-264.
39. Scolyer R.A., Murali R., McCarthy S.W., Thompson J.F. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol 2008, 25:100-111.
40. Scolyer R.A., Prieto V.G. Melanoma pathology: important issues for clinicians involved in the multidisciplinary care of melanoma patients. Surg Oncol Clin N Am 2011, 20:19-37.
41. Scolyer R.A., Thompson J.F., McCarthy S.W., et al. Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg 2005, 201:821-823. [author reply 823-4].
42. Stojadinovic A., Allen P.J., Clary B.M., et al. Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg 2002, 235:92-98.
43. Soo V., Shen P., Pichardo R., et al. Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology. Ann Surg Oncol 2007, 14:1612-1617.
44. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999, 17:976-983.
45. Cascinelli N., Bombardieri E., Bufalino R., et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006, 24:4464-4471.
46. Morton D.L., Cochran A.J., Thompson J.F., et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005, 242:302-311. [discussion 311-3].
47. Gershenwald J.E., Balch C.M., Soong S., Thompson J.F. Prognostic factors and natural history of melanoma. Cutaneous melanoma 2009, 35-64. Quality Medical Publishing, Inc., St. Louis, MO. C.M. Balch, A.N. Houghton, A.J. Sober, S.J. Soong, M.B. Atkins, J.F. Thompson (Eds.).
48. Wrightson W.R., Wong S.L., Edwards M.J., et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol 2003, 10:676-680.
49. Guggenheim M.M., Hug U., Jung F.J., et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. Ann Surg 2008, 247:687-693.
50. Kretschmer L., Thoms K.M., Peeters S., et al. Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versus complete regional lymph node dissection. Melanoma Res 2008, 18:16-21.
51. Daley M.D., Norman P.H., Leak J.A., et al. Adverse events associated with the intraoperative injection of isosulfan blue. J Clin Anesth 2004, 16:332-341.
52. Ross M.I., Gershenwald J.E. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)?. Ann Surg Oncol 2008, 15:670-673.
53. Gershenwald J.E., Andtbacka R.H., Prieto V.G., et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008, 26:4296-4303.
54. Govindarajan A., Ghazarian D.M., McCready D.R., Leong W.L. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 2007, 14:906-912.
55. Estourgie S.H., Nieweg O.E., Kroon B.B. High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg 2004, 91:1370-1371.
56. Thomas J.M., Clark M.A. Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 2004, 30:686-691.
57. Kang J.C., Wanek L.A., Essner R., et al. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 2005, 23:4764-4770.
58. Pawlik T.M., Ross M.I., Johnson M.M., et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005, 12:587-596.
59. Pawlik T.M., Ross M.I., Thompson J.F., et al. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005, 23:4588-4590.
60. van Poll D., Thompson J.F., Colman M.H., et al. A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005, 12:597-608.
61. Kruper L.L., Spitz F.R., Czerniecki B.J., et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 2006, 107:2436-2445.
62. McMasters K.M., Wong S.L., Edwards M.J., et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001, 130:151-156.
63. Rousseau D.L., Ross M.I., Johnson M.M., et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003, 10:569-574.
64. Agnese D.M., Abdessalam S.F., Burak W.E., et al. Cost-effectiveness of sentinel lymph node biopsy in thin melanomas. Surgery 2003, 134:542-547. discussion 547-8.
65. Kesmodel S.B., Karakousis G.C., Botbyl J.D., et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005, 12:449-458.
66. Thompson J.F., Shaw H.M. Sentinel node metastasis from thin melanomas with vertical growth phase. Ann Surg Oncol 2000, 7:251-252.
67. Thompson J.F., Soong S.J., Balch C.M., et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol 2011, 29:2199-2205.
68. Carlson G.W., Murray D.R., Hestley A., et al. Sentinel lymph node mapping for thick (>or=4-mm) melanoma: should we be doing it?. Ann Surg Oncol 2003, 10:408-415.
69. Gajdos C., Griffith K.A., Wong S.L., et al. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?. Cancer 2009, 115:5752-5760.
70. Gershenwald J.E., Mansfield P.F., Lee J.E., Ross M.I. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000, 7:160-165.
71. Jacobs I.A., Chang C.K., Salti G.I. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma. Am Surg 2004, 70:59-62.
72. Scoggins C.R., Bowen A.L., Martin R.C., et al. Prognostic information from sentinel lymph node biopsy in patients with thick melanoma. Arch Surg 2010, 145:622-627.
73. Lohmann C.M., Coit D.G., Brady M.S., et al. Sentinel lymph node biopsy in patients with diagnostically controversial spitzoid melanocytic tumors. Am J Surg Pathol 2002, 26:47-55.
74. Gannon C.J., Rousseau D.L., Ross M.I., et al. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer 2006, 107:2647-2652.
75. Balch C.M., Morton D.L., Gershenwald J.E., et al. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 2009, 60:872-875.